Cholesterol efflux potential and antiinflammatory properties of high-density lipoprotein after treatment with niacin or anacetrapib.
OBJECTIVE
To examine the effects of treatments with niacin or anacetrapib (an inhibitor of cholesteryl ester transfer protein) on the ability of high-density lipoprotein (HDL) to promote net cholesterol efflux and reduce toll-like receptor-mediated inflammation in macrophages.


RESULTS
A total of 18 patients received niacin, 2 g/d, for 4 weeks; 20 patients received anacetrapib, 300 mg/d, for 8 weeks; and 2 groups (n=4 and n=5 patients) received placebo. HDL samples were isolated by polyethylene glycol precipitation or ultracentrifugation, tested for the ability to promote cholesterol efflux in cholesterol-loaded THP-I or mouse peritoneal macrophages, or used to pretreat macrophages, followed by lipopolysaccharide exposure. HDL cholesterol levels were increased by 30% in response to niacin and by approximately 100% in response to anacetrapib. Niacin treatment increased HDL-mediated net cholesterol efflux from foam cells, primarily by increasing HDL concentration, whereas anacetrapib treatment increased cholesterol efflux by both increasing HDL concentration and causing increased efflux at matched HDL concentrations. The increased efflux potential of anacetrapib-HDL was more prominent at higher HDL cholesterol concentrations (>12 microg/mL), which was associated with an increased content of lecithin-cholesterol acyltransferase (LCAT) and apolipoprotein E and completely dependent on the expression of ATP binding cassette transporters (ABCA1 and ABCG1). Potent antiinflammatory effects of HDL were observed at low HDL concentrations (3 to 20 microg/mL) and were partly dependent on the expression of ABCA1 and ABCG1. All HDL preparations showed similar antiinflammatory effects, proportionate to the HDL cholesterol concentration.


CONCLUSIONS
Niacin treatment caused a moderate increase in the ability of HDL to promote net cholesterol efflux, whereas inhibition of cholesteryl ester transfer protein via anacetrapib led to a more dramatic increase in association with enhanced particle functionality at higher HDL concentrations. All HDLs exhibited potent ability to suppress macrophage toll-like receptor 4-mediated inflammatory responses, in a process partly dependent on cholesterol efflux via ABCA1 and ABCG1.
Yvan-Charvet
Laurent
L
Division of Molecular Medicine, Department of Medicine, Columbia University, 630 W 168th St, New York, NY 10032, USA. ly2159@columbia.edu
Kling
Jelena
J
Pagler
Tamara
T
Li
Hongna
H
Hubbard
Brian
B
Fisher
Tim
T
Sparrow
Carl P
CP
Taggart
Andrew K
AK
Tall
Alan R
AR
D064286:ATP Binding Cassette Transporter 1; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters / Q000235:genetics / Q000378:metabolism; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002478:Cells, Cultured; D002784:Cholesterol / Q000097:blood*; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D008076:Cholesterol, HDL / Q000097:blood*; D002986:Clinical Trials as Topic; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D005487:Foam Cells / Q000378:metabolism; D006801:Humans; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D007249:Inflammation / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D018836:Inflammation Mediators / Q000378:metabolism; D008074:Lipoproteins / Q000172:deficiency / Q000235:genetics / Q000378:metabolism; D008264:Macrophages / Q000276:immunology / Q000378:metabolism*; D051379:Mice; D018345:Mice, Knockout; D009525:Niacin / Q000009:adverse effects / Q000627:therapeutic use*; D023303:Oxazolidinones / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D051197:Toll-Like Receptor 4 / Q000378:metabolism; D016896:Treatment Outcome
C577836:ABCA1 protein, human; C487540:ABCG1 protein, mouse; D064286:ATP Binding Cassette Transporter 1; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters; D000893:Anti-Inflammatory Agents; C506642:CETP protein, human; D053480:Cholesterol Ester Transfer Proteins; D008076:Cholesterol, HDL; D000960:Hypolipidemic Agents; D018836:Inflammation Mediators; D008074:Lipoproteins; D023303:Oxazolidinones; C493487:Tlr4 protein, mouse; D051197:Toll-Like Receptor 4; D009525:Niacin; D002784:Cholesterol; C530884:anacetrapib
J Lipid Res. 1997 Apr;38(4):813-22
9144096
Nat Clin Pract Cardiovasc Med. 2007 Feb;4(2):102-9
17245404
Am J Cardiol. 2008 Mar 1;101(5):625-30
18308010
Clin Chem. 2008 May;54(5):788-800
18375481
J Lipid Res. 2000 Sep;41(9):1481-94
10974056
Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):877-82
19325144
Trends Cardiovasc Med. 2008 Feb;18(2):61-6
18308197
Immunity. 2004 Oct;21(4):561-74
15485633
J Lipid Res. 2007 Nov;48(11):2453-62
17761631
Br J Pharmacol. 2008 Aug;154(7):1465-73
18536749
Arterioscler Thromb Vasc Biol. 2010 Feb;30(2):139-43
19797709
N Engl J Med. 2007 Mar 29;356(13):1304-16
17387129
J Biol Chem. 1985 Oct 5;260(22):11934-43
2995353
Trends Cardiovasc Med. 2001 Apr-May;11(3-4):155-61
11686006
J Clin Invest. 1995 Dec;96(6):2882-91
8675659
N Engl J Med. 2007 Nov 22;357(21):2180-3
17984168
J Clin Invest. 1990 Sep;86(3):688-95
2118552
J Clin Invest. 2006 May;116(5):1435-42
16670775
Am J Cardiol. 2009 Jul 1;104(1):74-81
19576324
Arterioscler Thromb Vasc Biol. 2008 Nov;28(11):2071-7
18617650
Lancet. 2007 Dec 8;370(9603):1907-14
18068514
J Clin Invest. 2006 May;116(5):1226-9
16670767
Circulation. 2004 Dec 7;110(23):3512-7
15537681
J Lipid Res. 2007 Feb;48(2):299-306
17079792
N Engl J Med. 2007 Nov 22;357(21):2109-22
17984165
Curr Atheroscler Rep. 2007 Oct;9(4):249-51
18173946
Arterioscler Thromb Vasc Biol. 2009 Feb;29(2):268-75
19038848
Arterioscler Thromb Vasc Biol. 1998 Sep;18(9):1450-5
9743234
J Intern Med. 2008 Mar;263(3):256-73
18271871
Cardiol Clin. 2008 Nov;26(4):547-60
19031552
Arterioscler Thromb Vasc Biol. 2007 May;27(5):1132-8
17322101
Circulation. 2008 Dec 9;118(24):2506-14
19029466
Arterioscler Thromb Vasc Biol. 2005 Jun;25(6):1198-205
15831807
J Clin Invest. 1991 Dec;88(6):2039-46
1752961
J Lipid Res. 2009 Apr;50 Suppl:S145-9
18955731
Trends Cardiovasc Med. 2005 Aug;15(6):212-9
16182131
Nat Med. 2004 Apr;10(4):416-21
15034566
Cell Metab. 2008 May;7(5):365-75
18460328
Arterioscler Thromb Vasc Biol. 2004 Mar;24(3):490-7
14739125
N Engl J Med. 1990 Nov 1;323(18):1234-8
2215607
J Biol Chem. 2008 Aug 22;283(34):22930-41
18552351
Arterioscler Thromb Vasc Biol. 1995 Nov;15(11):1987-94
7583580
N Engl J Med. 2001 Nov 29;345(22):1583-92
11757504
J Lipid Res. 2004 Aug;45(8):1572-9
15145987
J Lipid Res. 2009 Feb;50(2):275-84
18827283
Curr Cardiol Rep. 2007 Nov;9(6):493-8
17999875
Nat Rev Drug Discov. 2008 Feb;7(2):143-55
18239670
Circulation. 2008 Oct 28;118(18):1837-47
18852364
J Biol Chem. 1985 Dec 25;260(30):16375-82
4066713
J Am Coll Cardiol. 1986 Dec;8(6):1245-55
3782631
Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10679-84
15249654
Am Heart J. 2009 Feb;157(2):352-360.e2
19185645
J Biol Chem. 1977 Oct 25;252(20):7288-93
198408
J Clin Invest. 2007 Mar;117(3):746-56
17332893